Redox Signs Licensing Agreement With OPKO Health, Inc.
On June 12, 2008, OPKO and Redox entered into an agreement whereby OPKO acquired the rights for all ophthalmic uses of Doxovir.
see OPKO Press Release

Redox Pharmaceutical Corporation has been granted approval from Health Canada to perform clinical studies on Herpes Labialis (cold sores).  Phase IB Clinical Trials (initial proof of safety and efficacy) have been successfully completed. A Phase II Clinical Trial on Herpes Labialis has been approved and has now been initiated.

We encourage you to contact us if you have any questions or would like additional information about Redox Pharmaceutical Corporation. Our corporate offices are located at:

Redox Pharmaceutical Corporation
Audubon Biomedical Science and Technology Park
3960 Broadway
New York, NY 10032
Tel: 212.543.4530
Fax: 212.543.4531
Email: info@redoxpharm.com